HLA ligands identified from DLBCL markers and disease-specific HLA ligands
| . | SUDHL-4 . | DB . | SUDHL-6 . | ||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| IFN-γ . | IFN-γ/ decitabine . | IFN-γ/ tazemetostat . | IFN-γ/ decitabine/tazemetostat . | Untreated . | IFN-γ . | IFN-γ/ decitabine . | IFN-γ/ tazemetostat . | IFN-γ/ decitabine/tazemetostat . | IFN-γ . | IFN-γ/ decitabine . | IFN-γ/ tazemetostat . | IFN-γ/ decitabine/tazemetostat . | |
| HLA ligands from proteins used as DLBCL markers | |||||||||||||
| BCL6 | LIHTGEKPY (B*15), RIHSGEKPY (B*15), SQSPQHAEM (B*15), TVHTGEKPY (B*15) | RIHSGEKPY (B*15), SQSPQHAEM (B*15), AITNTKVQY (B*15), TVHTGEKPY (B*15), GAITNTKVQY (B*15) | RIHSGEKPY (B*15), SQSPQHAEM (B*15), TVHTGEKPY (B*15), LIHTGEKPY (B*15) | RIHSGEKPY (B*15) | |||||||||
| CREBBP | AQAPAQSQF (B*15) | ||||||||||||
| CD79A/B | RVQEGNESY (B*15) | RVQEGNESY (B*15) | RVQEGNESY (B*15) | RVQEGNESY (B*15) | LLSAEPVPA (A*02) | DEYEDENLY (B*18), LLSAEPVPA (A*02), TELRVmGF (B*18) | DEYEDENLY (B*18), LLSAEPVPA (A*02), TELRVmGF (B*18) | DEYEDENLY (B*18), LLSAEPVPA (A*02), TELRVMGF (B*18) | DEYEDENLY (B*18), LLSAEPVPA (A*02), TELRVMGF (B*18), DENPQQLKL (B*18) | RVQEGNESY (B*15) | RVQEGNESY (B*15) | RVQEGNESY (B*15) | |
| PAX5 | YSHPQYSSY (B*15) | YSHPQYSSY (B*15) | |||||||||||
| HLA ligands not presented in healthy cells | |||||||||||||
| RGS13 | ATKYGPVVY (B*15) | ATKYGPVVY (B*15) | ATKYGPVVY (B*15) | FENLMATKY (B*18) | ATKYGPVVY (B*15) | ATKYGPVVY (B*15) | |||||||
| E2F8 | PQAPSGPSY (B*15) | PQAPSGPSY (B*15) | QEFDFIKSY (B*18) | QEFDFIKSY (B*18) | QEFDFIKSY (B*18) | PQAPSGPSY (B*15) | PQAPSGPSY (B*15) | ||||||
| . | SUDHL-4 . | DB . | SUDHL-6 . | ||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| IFN-γ . | IFN-γ/ decitabine . | IFN-γ/ tazemetostat . | IFN-γ/ decitabine/tazemetostat . | Untreated . | IFN-γ . | IFN-γ/ decitabine . | IFN-γ/ tazemetostat . | IFN-γ/ decitabine/tazemetostat . | IFN-γ . | IFN-γ/ decitabine . | IFN-γ/ tazemetostat . | IFN-γ/ decitabine/tazemetostat . | |
| HLA ligands from proteins used as DLBCL markers | |||||||||||||
| BCL6 | LIHTGEKPY (B*15), RIHSGEKPY (B*15), SQSPQHAEM (B*15), TVHTGEKPY (B*15) | RIHSGEKPY (B*15), SQSPQHAEM (B*15), AITNTKVQY (B*15), TVHTGEKPY (B*15), GAITNTKVQY (B*15) | RIHSGEKPY (B*15), SQSPQHAEM (B*15), TVHTGEKPY (B*15), LIHTGEKPY (B*15) | RIHSGEKPY (B*15) | |||||||||
| CREBBP | AQAPAQSQF (B*15) | ||||||||||||
| CD79A/B | RVQEGNESY (B*15) | RVQEGNESY (B*15) | RVQEGNESY (B*15) | RVQEGNESY (B*15) | LLSAEPVPA (A*02) | DEYEDENLY (B*18), LLSAEPVPA (A*02), TELRVmGF (B*18) | DEYEDENLY (B*18), LLSAEPVPA (A*02), TELRVmGF (B*18) | DEYEDENLY (B*18), LLSAEPVPA (A*02), TELRVMGF (B*18) | DEYEDENLY (B*18), LLSAEPVPA (A*02), TELRVMGF (B*18), DENPQQLKL (B*18) | RVQEGNESY (B*15) | RVQEGNESY (B*15) | RVQEGNESY (B*15) | |
| PAX5 | YSHPQYSSY (B*15) | YSHPQYSSY (B*15) | |||||||||||
| HLA ligands not presented in healthy cells | |||||||||||||
| RGS13 | ATKYGPVVY (B*15) | ATKYGPVVY (B*15) | ATKYGPVVY (B*15) | FENLMATKY (B*18) | ATKYGPVVY (B*15) | ATKYGPVVY (B*15) | |||||||
| E2F8 | PQAPSGPSY (B*15) | PQAPSGPSY (B*15) | QEFDFIKSY (B*18) | QEFDFIKSY (B*18) | QEFDFIKSY (B*18) | PQAPSGPSY (B*15) | PQAPSGPSY (B*15) | ||||||